Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.

Acta crystallographica. Section D, Biological crystallography - 1 Aug 2013

Anil Burcu, Riedinger Christiane, Endicott Jane A, Noble Martin E M

Abstract excerpt

The p53-binding site of MDM2 holds great promise as a target for therapeutic intervention in MDM2-amplified p53 wild-type forms of cancer. Despite the extensive validation of this strategy, there are relatively few crystallographically determined co-complex structures for small-molecular inhibito...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallization
Share to Crystallography, X-Ray
Share to Entropy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorescence Polarization

Share to Fluorometry

Share to Imidazoles

Share to Piperazines

Share to Proto-Oncogene Proteins c-mdm2

Source

Identifiers

PMID: 23897459
DOI: 10.1107/S0907444913004459

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23897459-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant.PMID 23897459Read ↗

Targeting the p53–MDM2 interaction to treat cancerSemantic proximity Read ↗

Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design.Semantic proximity Read ↗

Structural and sequential context of p53: A review of experimental and theoretical evidence.Semantic proximity Read ↗

Clinical Overview of MDM2/X-Targeted TherapiesSemantic proximity Read ↗

The Structure‐Based Design of Mdm2/Mdmx–p53 Inhibitors Gets SeriousSemantic proximity Read ↗

Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?Semantic proximity Read ↗

Targeting the MDM2 ‐ MDM4 interaction interface reveals an otherwise therapeutically active wild‐type p53 in colorectal cancerSemantic proximity Read ↗

Co-operative intra-protein structural response due to protein-protein complexation revealed through thermodynamic quantification: study of MDM2-p53 binding.Semantic proximity Read ↗

Patented inhibitors of p53–Mdm2 interaction (2006 – 2008)Semantic proximity Read ↗

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2Semantic proximity Read ↗

Structural basis for understanding oncogenic p53 mutations and designing rescue drugsSemantic proximity Read ↗

Small Molecule Antagonists of the MDM2 Oncoprotein as Anticancer AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.